Harrow Health (HROW) Rating Increased to Hold at ValuEngine

ValuEngine upgraded shares of Harrow Health (NASDAQ:HROW) from a sell rating to a hold rating in a research report report published on Monday morning, ValuEngine reports.

Several other equities research analysts also recently weighed in on HROW. Zacks Investment Research downgraded Harrow Health from a hold rating to a sell rating in a research report on Wednesday, March 13th. TheStreet raised Harrow Health from a d- rating to a c rating in a research report on Wednesday, May 1st.

Shares of NASDAQ HROW traded up $0.66 on Monday, hitting $6.52. The company had a trading volume of 7,468 shares, compared to its average volume of 150,330. Harrow Health has a 12-month low of $1.99 and a 12-month high of $7.20. The company has a debt-to-equity ratio of 0.47, a current ratio of 3.43 and a quick ratio of 3.22. The company has a market capitalization of $144.74 million, a price-to-earnings ratio of 10.49 and a beta of -0.02.

Harrow Health (NASDAQ:HROW) last issued its earnings results on Tuesday, March 12th. The company reported $0.77 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.84 by ($0.07). Harrow Health had a return on equity of 100.84% and a net margin of 65.84%. The company had revenue of $11.38 million during the quarter, compared to analysts’ expectations of $10.92 million. Research analysts expect that Harrow Health will post -0.1 EPS for the current fiscal year.

In related news, Director Robert J. Kammer sold 10,000 shares of the stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $6.91, for a total value of $69,100.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 30,000 shares of company stock valued at $162,500 in the last three months. 12.43% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently modified their holdings of HROW. Jane Street Group LLC acquired a new stake in Harrow Health in the 1st quarter valued at approximately $87,000. BlueCrest Capital Management Ltd bought a new position in Harrow Health during the 1st quarter valued at $125,000. Sio Capital Management LLC boosted its stake in Harrow Health by 61.4% during the 1st quarter. Sio Capital Management LLC now owns 541,114 shares of the company’s stock valued at $2,695,000 after purchasing an additional 205,750 shares in the last quarter. Morgan Stanley bought a new position in Harrow Health during the 1st quarter valued at $217,000. Finally, Oxford Asset Management LLP bought a new position in Harrow Health during the 1st quarter valued at $276,000. 24.18% of the stock is owned by hedge funds and other institutional investors.

Harrow Health Company Profile

Harrow Health, Inc owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients.

Read More: What is a trade deficit?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.